OKLAHOMA CITY, April 23, 2018 -- Federman & Sherwood announces that on April 20, 2018, a class action lawsuit was filed in the United States District Court for the District of Utah against Myriad Genetics, Inc. (NASDAQ:MYGN). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is August 13, 2014 through March 12, 2018.
Plaintiff seeks to recover damages on behalf of all Myriad Genetics, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Tuesday, June 19, 2018 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.
If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact:
Robin Hester
FEDERMAN & SHERWOOD
10205 North Pennsylvania Avenue
Oklahoma City, OK 73120
Email to: [email protected]
Or, visit the firm’s website at www.federmanlaw.com


Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
OpenAI Hires OpenClaw Creator Peter Steinberger to Advance Next-Generation AI Agents
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal
How Marco Pharma International Preserves German Homeopathic Traditions in America
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 



